Annexon's R&D Surge Fuels 77% Net Loss Increase

Ticker: ANNX · Form: 10-Q · Filed: Nov 10, 2025 · CIK: 1528115

Sentiment: bearish

Topics: Biotechnology, Clinical Trials, R&D Spending, Net Loss, Liquidity Risk, Neuroinflammation, Biopharmaceutical

Related Tickers: ANNX

TL;DR

**ANNX is burning cash at an alarming rate to fund R&D, making it a high-stakes bet on pipeline success.**

AI Summary

Annexon, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $158.4 million, up from $89.6 million in the same period of 2024. This 76.8% increase was primarily driven by a substantial rise in research and development (R&D) expenses, which surged to $142.0 million in 2025 from $76.1 million in 2024, representing an 86.6% increase. The company's cash and cash equivalents increased to $139.4 million as of September 30, 2025, from $49.5 million at December 31, 2024, while short-term investments decreased from $262.5 million to $49.3 million over the same period. Total assets declined from $350.1 million to $229.1 million. Annexon continues to fund operations through equity issuances, with additional paid-in capital increasing to $1,030.5 million from $1,003.7 million. The company projects existing cash and short-term investments will fund operations for at least 12 months, but future viability depends on securing additional funding and achieving development milestones.

Why It Matters

Annexon's escalating R&D spend, up 86.6% to $142.0 million, signals aggressive pursuit of its neuroinflammation pipeline, which could be a high-reward, high-risk strategy for investors. While the increased burn rate led to a $158.4 million net loss, successful clinical trial outcomes could significantly boost ANNX's competitive position against other biopharmaceutical firms in the neuroinflammatory disease space. Employees face continued pressure to deliver on development milestones, and customers await potential new treatments. The broader market will watch for signs of clinical progress, as this could validate Annexon's complement-mediated approach and impact valuations across the biotech sector.

Risk Assessment

Risk Level: high — Annexon reported an accumulated deficit of $869.1 million as of September 30, 2025, and a net loss of $158.4 million for the nine months ended September 30, 2025. The company explicitly states it expects to incur losses and negative cash flows for at least the next several years, and its future viability beyond 12 months is dependent on obtaining additional funding, which carries significant uncertainty.

Analyst Insight

Investors should closely monitor Annexon's upcoming clinical trial results and any announcements regarding new financing rounds. Given the high burn rate and reliance on future funding, a speculative position might be considered only after clear positive data from its late-stage clinical platform, or if a strategic partnership is announced.

Financial Highlights

debt To Equity
N/A
revenue
N/A
operating Margin
N/A
total Assets
$229.1M
total Debt
N/A
net Income
-$158.4M
eps
-$1.08
gross Margin
N/A
cash Position
$139.4M
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What were Annexon's key financial results for the nine months ended September 30, 2025?

Annexon reported a net loss of $158.4 million for the nine months ended September 30, 2025, a significant increase from $89.6 million in the prior year. Research and development expenses were $142.0 million, up from $76.1 million.

How much cash and short-term investments does Annexon have as of September 30, 2025?

As of September 30, 2025, Annexon had $139.4 million in cash and cash equivalents and $49.3 million in short-term investments, totaling $188.7 million. This is down from $312.0 million at December 31, 2024.

What is Annexon's accumulated deficit as of September 30, 2025?

Annexon's accumulated deficit as of September 30, 2025, was $869.1 million, reflecting the company's ongoing losses since its inception in March 2011.

What is the outlook for Annexon's liquidity?

Management projects that existing cash and cash equivalents and short-term investments will enable Annexon to fund its operating expenses and capital expenditure requirements for at least twelve months from the date of issuance of these financial statements. However, future viability beyond that point depends on obtaining additional funding.

What are the primary risks to Annexon's future operations?

The primary risks include uncertainties in obtaining additional equity or debt financing on favorable terms, entering into collaborative agreements with strategic partners, and succeeding in its future operations, particularly given the expectation of continued losses and negative cash flows.

How did Annexon's research and development expenses change year-over-year?

Research and development expenses increased substantially, rising from $76.1 million for the nine months ended September 30, 2024, to $142.0 million for the same period in 2025, an 86.6% increase.

What is Annexon's business focus?

Annexon, Inc. is a biopharmaceutical company focused on advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated neuroinflammatory diseases of the body, brain, and eye.

Has Annexon adopted any new accounting pronouncements recently?

Yes, Annexon adopted ASU 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosures, on January 1, 2024, for annual requirements and January 1, 2025, for interim requirements. This adoption did not have a material impact on the consolidated financial statements.

What was the net loss per share for Annexon for the nine months ended September 30, 2025?

The net loss per share, basic and diluted, for Annexon for the nine months ended September 30, 2025, was $1.08, compared to $0.68 for the same period in 2024.

How many shares of common stock were outstanding for Annexon as of November 5, 2025?

As of November 5, 2025, the number of shares of Annexon's Common Stock outstanding was 119,632,804. This excludes 38,543,577 shares issuable upon the exercise of pre-funded warrants.

Risk Factors

Industry Context

Annexon operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing therapies for autoimmune and neurodegenerative diseases. The industry is characterized by long development cycles, significant R&D investment, and high regulatory hurdles. Success hinges on innovation, clinical trial efficacy, and securing substantial funding to navigate these challenges.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Annexon is subject to stringent regulatory oversight by bodies like the FDA. The success of its drug candidates hinges on rigorous clinical trials and eventual regulatory approval, which are complex, lengthy, and uncertain processes.

What Investors Should Do

  1. Monitor R&D spending and clinical trial progress closely.
  2. Assess the company's ability to secure future funding.
  3. Evaluate the competitive landscape and differentiation of Annexon's platform.

Key Dates

Glossary

Net Loss
The total expenses of a company exceed its total revenues over a specific period. (Annexon reported a substantial increase in net loss, indicating significant operational costs outpacing revenue.)
Research and Development (R&D) Expenses
Costs incurred by a company in the process of developing new products or services, or improving existing ones. (A primary driver of Annexon's increased net loss, reflecting investment in its drug development pipeline.)
Cash and Cash Equivalents
Highly liquid financial instruments with original maturities of three months or less. (Represents Annexon's immediate liquidity, which increased but is being utilized to fund operations.)
Short-term Investments
Investments with maturities of more than three months but less than one year. (A significant portion of Annexon's assets that has been depleted, indicating cash expenditure.)
Accumulated Deficit
The cumulative net losses of a company since its inception, less any net gains. (Shows the long-term financial impact of Annexon's ongoing operational losses.)
Additional Paid-in Capital
The amount of money a company receives from selling stock above its par value. (Indicates that Annexon continues to rely on equity financing to fund its operations.)

Year-Over-Year Comparison

Annexon's financial performance shows a marked deterioration compared to the prior year. The net loss for the nine months ended September 30, 2025, increased by 76.8% to $158.4 million, primarily driven by an 86.6% surge in R&D expenses to $142.0 million. While cash and cash equivalents saw an increase, this was offset by a substantial draw-down of short-term investments, indicating a higher cash burn rate. Total assets have also declined, reflecting the utilization of capital to fund ongoing operations and development.

Filing Stats: 4,360 words · 17 min read · ~15 pages · Grade level 17.2 · Accepted 2025-11-10 16:10:50

Key Financial Figures

Filing Documents

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations 2 Condensed Consolidated Statements of Comprehensive Loss 3 Condensed Consolidated Statements of Stockholders' Equity 4 Condensed Consolidated Statements of Cash Flows 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 27 Item 4.

Controls and Procedures

Controls and Procedures 27

—OTHER INFORMATION

PART II—OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 28 Item 1A.

Risk Factors

Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 72 Item 3. Defaults Upon Senior Securities 72 Item 4. Mine Safety Disclosures 72 Item 5. Other Information 72 Item 6. Exhibits 73

SIGNATURES

SIGNATURES 74 In this Quarterly Report on Form 10-Q, "we," "our," "us," "Annexon" and the "Company" refer to Annexon, Inc. and its consolidated subsidiary. Annexon, Annexon, Inc., the Annexon logo and other trade names, trademarks or service marks of Annexon are the property of Annexon, Inc. This report contains references to our trademarks and to trademarks belonging to other entities. Trade names, trademarks and service marks of other companies appearing in this report are the property of their respective holders. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. ANNEXON, INC. Condensed Consolidated Balance Sheets (in thousands) September 30, 2025 December 31, 2024 (Unaudited) Assets Current assets: Cash and cash equivalents $ 139,419 $ 49,498 Short-term investments 49,302 262,519 Prepaid expenses and other current assets 4,101 4,444 Total current assets 192,822 316,461 Restricted cash 1,032 1,032 Property and equipment, net 11,152 12,638 Operating lease right-of-use assets 15,587 16,705 Other non-current assets 8,549 3,235 Total assets $ 229,142 $ 350,071 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 18,219 $ 10,426 Accrued and other current liabilities 22,543 17,568 Operating lease liabilities, current 2,818 2,518 Total current liabilities 43,580 30,512 Operating lease liabilities, non-current 24,120 26,454 Total liabilities 67,700 56,966 Commitments and contingencies (Note 5) Stockholders' equity: Common stock 115 109 Additional paid-in capital 1,030,536 1,003,685 Accumulated other comprehensive (loss) income ( 76 ) 10 Accumulated deficit ( 869,133 ) ( 710,699 ) Total stockholders' equity 161,442 293,105 Total liabilities and stockholders' equit

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing